Clinical Trial Update: Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation [NA]

View source ↗

Summary

A clinical trial evaluating telmisartan to prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation was terminated; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Telmisartan (Telmisartan)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: GVHD | NA | Status: TERMINATED | Results posted: 2024-05-01